NEWS

WIRES

OTHER

Intrinsik Announces Acquisition of Carexa Inc.

Intrinsik Health Sciences Inc. (Intrinsik), a leading provider of toxicology, product development and regulatory affairs consulting services, is pleased to announce the acquisition of Carexa Incorporated (Carexa), a regulatory affairs consulting firm which currently does business in North America and Europe. With this acquisition comes the appointment of Dr. Jan Sedgeworth as Vice President, Regulatory Affairs for Intrinsik Health Sciences Inc., the pharmaceutical and biologics consulting division of Intrinsik Inc.

The addition of Carexa and, specifically, Jan to the Intrinsik family is consistent with our philosophy of providing senior, personalized advice and hands-on solutions to our clients. Intrinsik feels that Jan's leadership and personality are a perfect complement to our existing team of experienced professionals. In addition, the acquisition of Carexa solidifies Intrinsik's reputation as a provider of comprehensive and strategic regulatory services. Jan's years of experience in multinational pharmaceutical companies, emerging biotech and consulting, coupled with Intrinsik's recent implementation of eSubmission software will allow us to provide our clients with the most current information and approaches to filing their submissions.

Dr. Jon Daniels, Executive VP, Intrinsik, commented that "this solidifies a long standing business relationship and will benefit both Carexa and Intrinsik clients in the future."

About Intrinsik

Intrinsik Health Sciences Inc. is an independent consultancy whose focus is to address the toxicology and regulatory challenges associated with the development of new products. We help our clients manage the risks associated with product development through recognizing and understanding the scientific and regulatory issues that will impact their programs and designing and implementing optimal product development and regulatory strategies. In the last seven years, the team has been responsible for successfully driving over 70 nonclinical development programs for new human therapeutics. In addition, the team has been responsible for the preparation of numerous INDs (senior staff have been actively involved in over 100 successful INDs) and contributed to more than 20 NDAs during their careers.

With this acquisition, Intrinsik continues to be a privately-held, independent provider of superior preclinical, regulatory, and toxicology consulting services. Both Intrinsik and Carexa have well-established reputations for providing solid regulatory strategy and operational support to both emerging and larger pharmaceutical.